Longevity Startups

23andMe operates a research platform that collects genetic data from millions of users to advance genomic research and health discovery. The company enables individuals to learn about their genetic traits while contributing to medical research studies that benefit public health.

13 investors

NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology. The company builds therapeutic programs that aim to engineer cell identity and reprogram cell age for human patients.

11 investors

Aspect Biosystems is a Canadian biotechnology company developing Bioprinted Tissue Therapeutics—implantable engineered tissues designed to replace, repair, or supplement biological function—for the treatment of diseases such as type 1 diabetes. It operates in the regenerative medicine field and has partnered with pharmaceutical companies including Novo Nordisk.

10 investors

BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases. The company uses data-driven approaches and bioinformatics to identify and develop its pipeline of aging-focused therapeutics.

9 investors

Juvena Therapeutics develops biologics derived from human secreted proteins to treat aging-related diseases, using AI-enabled drug discovery to identify tissue-restorative therapeutics for muscle and metabolic disorders.

9 investors

Loyal develops therapeutics to help dogs live longer and healthier lives, focusing on canine aging research and longevity interventions for companion dogs.

9 investors

Tembo Health provides care coordination and management services for seniors, particularly those with chronic conditions and dementia. The platform aims to simplify the healthcare journey for older adults by improving access to physicians and streamlining chronic disease management.

9 investors

Generation Lab offers an at-home epigenetic aging test (SystemAge) that measures 460 biomarkers across 21 organs and systems using DNA methylation, delivering a personalized aging report and action plan for consumers. It uses a needle-free blood collection device and connects users to a network of longevity clinics for follow-up consultations and retesting.

8 investors

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.

7 investors

Assured Allies provides insurance and health engagement solutions for older adults, partnering with financial institutions to deliver preventive care and protection services. The company serves financial institutions and their policyholders aged 60+.

7 investors

Retirable offers holistic retirement planning through dedicated fiduciary financial advisors, providing customized investment plans, reliable monthly retirement income, high-yield cash savings, and $1M in identity theft protection. It serves individuals planning for and living in retirement.

7 investors

Rubedo Life Sciences develops therapeutics targeting aging by eliminating senescent cells to extend human healthspan. The company applies artificial intelligence and chemistry to drug discovery in the longevity and regenerative medicine space.

7 investors

Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability. The company uses human genetic data and clinical expertise to select drug targets in the obesity treatment landscape.

6 investors

Cambrian Biopharma develops medicines targeting metabolic pathways that decline with age, aiming to treat and eventually prevent chronic metabolic disease and extend healthspan. It operates a drug sourcing and development model that advances a portfolio of drug candidates across multiple pipeline programs.

6 investors

Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders. The company serves patients with conditions driven by cellular aging and senescence.

6 investors

Gordian Biotechnology develops therapies aimed at treating age-related diseases to extend healthy lifespan. It operates in the biotechnology and longevity space.

6 investors

Isaac Health provides virtual, interdisciplinary care for people experiencing memory and thinking changes, staffed by board-certified neurologists, geriatric specialists, neuropsychologists, speech-language pathologists, and care navigators. It offers nationwide telehealth services in the US focused on diagnosing, treating, and supporting patients with cognitive conditions.

6 investors

Qida provides in-home care services for elderly and dependent people in Spain, matching families with professional caregivers on a flexible basis (from one hour a week to live-in 24/7 care) with ongoing supervision by psychologists or social workers. It also offers complementary services such as physiotherapy, help contracting caregivers, and assistance managing public dependency-law subsidies.

6 investors

RubyWell connects family caregivers of homebound older adults with Medicare Advantage plans and home health agencies, offering care navigation support, training, and monthly stipends through a structured study program. Its technology helps caregivers identify early health signals and access Medicare-covered home health services to reduce avoidable hospitalizations for chronically ill patients in the US.

6 investors

Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients. It operates in oncology-focused drug discovery and development.

5 investors

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration. The company focuses on patients with neurodegenerative conditions and applies genetics, neuroscience, and immunology to advance new treatments.

5 investors

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

5 investors

General Control is a research company working on epigenetic modulation, staffed by scientists, inventors, and clinicians. It develops therapeutic approaches based on epigenetics.

5 investors

GlycanAge offers an at-home biological age test that analyzes IgG glycan patterns to measure chronic inflammation ("inflammaging") and its effect on aging. Customers use a finger-prick kit, receive a report on their glycan indexes and biological age, and get a 1:1 interpretation call with a specialist.

5 investors